Key Responsibilities Strategic Leadership & Transformative Vision • Drive pipeline differentiation by identifying high-value targets and novel E3 ligases aligned with unmet medical needs. • Ensure the company maintains a competitive edge through adoption of innovative modalities, AI-enabled drug discovery, and multi-omics integration. • Provide scientific input to corporate strategy, BD, and fundraising discussions. Platform Innovation & Technology Integration • Architect and scale a fully integrated discovery engine combining: o Chemistry: DEL, CIP-DEL, fragment-based, medicinal chemistry optimization. o Biology: chemoproteomics, cell-based degradation assays, translational biomarkers. o Computation: AI-enabled VS, structural modeling (AlphaFold3, MD simulations), multi-omics data mining. • Guide structural biology programs (X-ray crystallography, Cryo-EM, NMR) to support rational molecular glue design. • Oversee development of robust PK/PD, ADME, and safety packages to de-risk early candidates. Pipeline Development • Lead programs from hit discovery through lead optimization, PCC, and IND- enabling studies, with a strong focus on inflammation, autoimmune diseases, and CNS disorders. • Establish rigorous decision-making frameworks to prioritize assets and allocate resources across therapeutic areas with high unmet need. • Define and enforce clear Go/No-Go milestones that balance scientific innovation with capital efficiency.

Qualifications • PhD in Medicinal Chemistry, Chemical Biology, Structural Biology, or a related discipline. • Over 10 years of experience in small-molecule drug discovery, with deep expertise in structure-based drug design and translational research. • Minimum of 5 years leading Targeted Protein Degradation (TPD) programs, including PROTACs, molecular glues, or E3 ligase modulation, with a strong track record of advancing assets from hit identification through PCC and IND- enabling studies. • Extensive knowledge of E3 ligase biology, PPI modulation, and molecular glue mechanisms, including the design and optimization of novel degrader modalities. • Demonstrated leadership in deploying cutting-edge discovery technologies such as DNA-encoded libraries (DEL/CIP-DEL), chemoproteomics, fragment-based screening, and AI-driven virtual screening platforms. • Proven ability to lead cross-functional teams, collaborate with external partners, and translate complex biology into differentiated clinical candidates.